ABPI names president elect

Deepak Khanna takes up full role in April 2012

Deepak Khanna, senior vice president and md of MSD UK, has been named as president elect of the Association of the British Pharmaceutical Industry (ABPI).

Khanna will succeed current ABPI president Simon Jose of GSK after the 2012 ABPI AGM in April. He will initially serve for one year, with the option of re-election for a further 12 months.

‘I am absolutely delighted and deeply honoured to have been given the opportunity to lead the representation of the industry at this challenging time for the pharmaceutical sector,’ said Khanna.

‘The Government's proposals for a new pricing system for branded medicines, the reforms of the NHS, and the recommendations of the Nicholson Review of Innovation mean it is vital for the industry to have a strong and united voice.’

Khanna, who began his career with Merck in 1988, previously managed all aspects of the US Merck/Schering-Plough joint venture, and was responsible for the US marketing and sales for the two cardiovascular products jointly marketed by the two companies. After the announcement of plans to merge with Schering-Plough (March 2009), he also led the US integration planning efforts.

You may also like

Research & Development

Scotland’s manufacturing exports worth £462 million

The Scottish pharmaceutical industry is ‘booming’ and is now the second biggest spender on R&D, a new report has revealed
Regulatory

UK clinical research post-Brexit

Dr Sheuli Porkess, Deputy Chief Scientific Officer of the ABPI here discusses the future of clinical research as the UK prepares to leave the EU
Media

Life Sciences sector responds to report on the impact of Brexit

The Business, Energy and Indsutrial Strategy (BEIS) Committee report calls on the Government to secure a post-Brexit deal to protect patients and the UK's pharmaceutical industry
Media

Life Science Industry Coalition position paper released

The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have launched a joint policy document on the potential impact of the UK’s exit from the EU
Media

Safeguarding public health must be number one priority

To coincide with the House of Commons Health Select Committee on <i>Brexit: the regulation of medicines, medical devices and substances of human origin</i>, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have published new research on the public health implications of Brexit
Research & Development

New Lung Health Taskforce to tackle Britain’s third biggest killer

The Association of the British Pharmaceutical Industry (ABPI) and the British Lung Foundation (BLF) have launched a new Taskforce for Lung Health that will work, in collaboration, to produce a new national 5 year prevention, diagnosis and treatment plan for lung health
Research & Development

Life sciences leaders welcome Brexit position paper on future of UK science

The ABPI and the BIA have welcomed the UK Government’s latest Brexit position paper on <i>Collaboration on science and innovation</i>
Subscribe now